Intellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from Wedbush

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)'s stock had its "neutral" rating reiterated by Wedbush in a research note issued to investors on Monday,RTT News reports. They presently have a $7.00 price target on the stock. Wedbush's price target indicates a potential downside of 21.08% from the stock's current price.

A number of other research analysts also recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research report on Monday. Canaccord Genuity Group reduced their target price on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating for the company in a research note on Tuesday, June 3rd. The Goldman Sachs Group reissued a "sell" rating and issued a $9.00 price target on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Finally, Barclays cut their target price on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $34.95.

Intellia Therapeutics Stock Up 6.7%

Shares of NASDAQ NTLA traded up $0.56 during mid-day trading on Monday, reaching $8.87. 2,988,969 shares of the company were exchanged, compared to its average volume of 2,820,918. The firm has a 50-day moving average of $8.09 and a 200 day moving average of $9.79. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.18. The stock has a market cap of $918.78 million, a price-to-earnings ratio of -1.63 and a beta of 2.14.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The company had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. The firm's revenue for the quarter was down 42.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.12) EPS. On average, equities analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $43,177,000. Voloridge Investment Management LLC lifted its holdings in shares of Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company's stock worth $17,805,000 after purchasing an additional 1,059,751 shares during the period. Contrarius Group Holdings Ltd acquired a new stake in shares of Intellia Therapeutics in the 4th quarter worth $11,798,000. Two Sigma Advisers LP lifted its holdings in shares of Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock valued at $23,300,000 after buying an additional 970,700 shares during the period. Finally, Two Sigma Investments LP boosted its position in shares of Intellia Therapeutics by 88.1% during the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock worth $21,498,000 after purchasing an additional 863,363 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.